Streetbeat News

Analyst Ratings

DD

In the last three months, 8 financial analysts have published diverse ratings on DuPont de Nemours (NYSE:DD), with a shift towards a more cautious stance in the last 30 days. The average 12-month price target is now $75.25, down 5.64% from the previous target. Analyst actions include both downgrades and upgrades, reflecting dynamic market conditions and DuPont's performance. Despite challenges such as a -5.23% decline in revenue growth and below-industry benchmarks in ROE and ROA, DuPont maintains a strong market presence with a superior market capitalization and efficient cost management.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 6:00 pm

ADI

Analyst ratings for Analog Devices (NASDAQ:ADI) over the past quarter show a mix of opinions, with a recent shift towards a more neutral stance. The latest 12-month price targets suggest an average of $205.45, marking a 2.8% increase from the previous $199.86. Despite diverse analyst opinions, the company faces financial challenges, including a -16.36% revenue decline as of October 31, 2023, and below-average performance metrics such as net margin and ROE compared to industry peers.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 6:00 pm

WAT

Analysts have updated their ratings and price targets for Waters Corporation (NYSE:WAT), showing a positive shift in sentiment. Over the past quarter, 4 analysts have provided diverse opinions, with recent updates indicating a move towards more favorable views. The average 12-month price target for WAT has increased to $301.25, up 13.68% from the previous $265.00. This change reflects analysts' responses to market dynamics and Waters's performance, including its strong financial indicators such as revenue growth, net margin, ROE, and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 6:00 pm

ITI

EF Hutton analyst Tim Moore has maintained a Buy rating on Iteris (NASDAQ:ITI) and increased the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 5:58 pm

ANTX

Evercore ISI Group analyst Liisa Bayko downgraded AN2 Therapeutics (NASDAQ:ANTX) from Outperform to In-Line and reduced the price target from $25 to $7.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 5:54 pm

BTCUSD

ETHUSD

SOLUSD

Raoul Pal predicts Bitcoin could reach $250,000, Ethereum could hit $15,000-$20,000, and Solana could rise to $750-$1,000 in the next 18 months due to currency debasement and the transformative potential of digital assets. He discussed these views with Anthony Scaramucci, highlighting the importance of cryptocurrencies in preserving wealth amidst global financial system issues.

Portfolio Pulse from Murtuza Merchant

February 12, 2024 | 5:49 pm

HSY

Morgan Stanley analyst Pamela Kaufman downgraded The Hershey Co (NYSE:HSY) to Underweight from Equal-Weight with a reduced price target of $183 from $191, citing concerns over cocoa inflation, pricing environment, and consumer demand. Despite a slight sales increase in Q4 fiscal 2023, Hershey's sales missed consensus, and its 2025 EPS estimate was lowered due to expected input cost inflation and gross margin contraction.

Portfolio Pulse from Lekha Gupta

February 12, 2024 | 5:48 pm

SGMO

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Sangamo Therapeutics (NASDAQ:SGMO) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 5:48 pm

ALNY

Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals (ALNY) and maintained a $165 price target.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 5:46 pm

TXN

Cantor Fitzgerald analyst C J Muse has reiterated a Neutral rating on Texas Instruments (TXN) and maintained a $170 price target.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 5:43 pm